The purpose of this study was to translate into Polish and validate the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Ophthalmic Module (QLQ-OPT30). The QLQ-OPT30 was translated and pilot-tested according to EORTC guidelines. Patients were qualified based on the histological or ophthalmoscopic and ultrasonographic diagnosis of uveal melanoma. Each patient filled out the Polish version of the EORTC Quality of Life Questionnaire (EORTC QLQ-C30), the QLQ-OPT30 module and a personal questionnaire. Patients were divided into three groups according to treatment type, melanoma localisation and possible negative outcomes of the disease or treatment. Reliability and validity test were performed and patients' comments were analysed. Our study included 94 patients--50 women (53.2%) and 44 men (46.8%) in the mean age of 58.4 (±13) years. Treatment type and melanoma location did not influence the health-related quality of life. The QLQ-OPT30, apart from two scales, showed positive internal consistency (Cronbach's alpha coefficients range: 0.70-0.88). We found the Polish version of the EORTC QLQ-OPT30 module a useful tool for measuring health-related quality of life in uveal melanoma patients. Although its discriminative validity is somewhat limited it still can be recommended for clinical use in the Polish population.
Uveal melanoma is a rare malignancy in children and teenagers. In the present series, it occurred in the iris in more than 50% of cases.
Aim: The fluorophotometric evaluation of the blood-retinal barrier (BRB) integrity in patients with essential hypertension (EH) without signs of BRB damage. Material and Methods: 55 subjects participated in the study: 36 patients with EH and 19 normotensive healthy volunteers; 22 men and 33 women. The protocol included ophthalmic examination, fluorescein angiography, fluorophotometry, laboratory tests (total cholesterol, LDL and HDL cholesterol, triglycerides, fibrinogen, serum creatinine concentration, fasting glucose concentration, oral glucose test), urinary cotinine concentration measurement and cotinine-creatinine ratio (CCR) calculation. Results: BRB permeability (PBRB) in patients with EH was significantly higher than in the control group (2.24 ± 0.68 vs. 1.64 ± 0.64 nm/s; p = 0.003). In hypertensive patients with CCR >50 ng/mg, the PBRB was significantly higher than the PBRB in healthy volunteers not exposed to smoke (2.32 vs. 1.68 nm/s; p < 0.05). Conclusions: The PBRB in patients with EH is significantly higher than that in the normotensive control group, which shows the damaging effect of EH on the BRB.
Purpose Analysis of patients with conjunctival melanoma. Methods Retrospective analysis of 61 consecutive patients with histopathologic diagnosis of conjunctival melanoma treated between 1991‐2007 at the Department of Ophthalmology and Ocular Oncology of Jagiellonian University in Krakow. There were 30 (49.2%) women and 31 (50.8%) men in mean age of 57.6 years (25‐89). Results The tumors involved in 29 cases right eye and in 32 cases left eye. 26 (42.6%) melanomas were located in temporal quadrant; 37 (60.6%) tumors involved limbus and 22 (36.1%) bulbar conjunctiva; in 2 (3.3%) patients tumors infiltrated tarsal conjunctiva. 53 tumors (86.9%) were pigmented, 5 (8.2%) ‐ amelanotic and 3 tumors (4.9%) ‐ mixed. In 59 (96.7%) patients the tumors were nodular and in 2 (3.3%) diffuse, superficial. In all cases surgical excision was performed and in 44 (73.13%) cases adjunctive Ru‐106 brachytherapy. In 20 (32.7%) cases recurrence of melanoma necessitating secondary treatment was observed. The mean time to recurrence was 24.65 months (2‐91). In 5 (8%) cases documented metastasis occurred. Among all patients 5 (8%) died because of metastatic disease, 3 because of other reasons. 6 cases were lost to follow‐up because they moved to other countries. Conclusion Conjunctival melanoma most commonly occurs in form of a melanocytic, nodular tumor localized in corneal limbus and bulbar conjunctiva. Local recurrence of the tumor may be expected despite the surgical excision combined with adjunctive therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.